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Results Over a 20-year time horizon, events occurred in 
7.2 % of the population after screening, and in 8.5 % of the 
population without screening. QALYs increased from 16.37 
(no screening strategy) to 16.40 (screening strategy), an in-
crement of 0.03 (95 % CI 0.01;0.05) QALYs. Total expected 
costs were € 8016 in the screening strategy, and € 9087 
in the none screening strategy (expected saving of € 1071 
(95 % CI − 3146;-87) per person).
Conclusion Annual hypertension screening and treatment 
in women with a history of preeclampsia may save costs, for 
at least a similar quality of life and survival due to prevented 
CVD compared with standard care.
Keywords Preeclampsia · Economic analysis · 
Cardiovascular screening
Introduction
It has been well established that women with a history of 
preeclampsia are at increased risk of future cardiovascular 
disease (CVD) morbidity and mortality [1]. Preeclampsia is 
defined as de novo hypertension (140/90 mmHg) with pro-
teinuria (> 0.3 g/24 h) occurring in the second half of preg-
nancy [2]. Despite the abundant evidence on the increased 
CVD risk in these women later in life, [3, 4] intermediate 
follow-up data are still relatively scarce and it is still unde-
fined whether preventive measures are needed [5].
In the Preeclampsia Risk EValuation in FEMales (PRE-
VFEM) cohort, consisting of 339 women with a history of 
early preeclampsia (before 32 weeks of pregnancy), we pre-
viously identified hypertension as the most important CVD 
risk factor at a cardiovascular screening 10 years post-par-
tum [6]. As hypertension is an established CVD risk factor 
[7], early detection and treatment of hypertension is of pri-
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Background Women with a history of preeclampsia are at 
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Methods A decision-analytic Markov model was con-
structed to evaluate healthcare costs and effects of screen-
ing and treatment (100 % compliance) for hypertension 
post preeclampsia based on the available literature. Cardio-
vascular events and CVD mortality were defined as health 
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sitivity and threshold analyses were performed to address 
uncertainty.
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mary importance for this category of young women. How-
ever, screening onwards from pregnancy is labour-intensive 
and may be costly. Currently, few data on cost-effectiveness 
of preventive interventions in women after preeclampsia are 
available; however, data on women after early preeclamp-
sia are not available [8]. We performed a model-based cost-
effectiveness analysis to estimate the healthcare costs and 
potential effects of screening for hypertension in women 
with a history of early preeclampsia.
Methods
Overview
A decision-analytic Markov model was constructed to eval-
uate costs and effects of screening for hypertension from 
a healthcare perspective in women post preeclampsia. In 
each cycle of the model patients were transferred to a cer-
tain health state according to the further described transition 
probabilities. The predefined health states are demonstrated 
in Fig. 1. The cycle length was one year. We used time hori-
zons of 10 and 20 years, the starting point was at 30 years 
of age. Outcomes were measured in number of events, life-
years, quality-adjusted life-years (QALYs) and absolute 
costs. The Markov model was built and analysed in Micro-
soft Office Excel 2010.
Model construction
Patient characteristics
As target population we used the PREVFEM cohort, com-
prising women with a history of early-onset preeclampsia 
(onset before 32 weeks of pregnancy).[6] This study was 
performed to evaluate the presence of CVD risk factors in 
women at 10 years after index pregnancy. The detailed pro-
tocol of the screening procedure has been described else-
where.[6]
Comparators
We introduced a hypothetical annual blood pressure 
screening at the general practitioner (GP) for women after 
preeclampsia, starting in the first-year postpartum. The com-
parative strategy existed of care as usual: standard obstetric 
care  and  no  specifically  arranged  blood  pressure  check-
ups. If hypertension was detected in any of the strategies, 
this involved three additional GP visits, an ECG recording 
and prescription of medication. The probability of devel-
oping CVD with and the probability without hypertension 
were equal between the two strategies. The only difference 
between the strategies was in detecting and therefore treat-
ing hypertension.
Transition probabilities
Risk of hypertension and presence of adequate treatment for 
women after preeclampsia were based on the PREVFEM 
cohort [6]. As the follow up in this cohort is relatively short 
(10 years) we used published literature to assess the risk of 
future CVD in women post preeclampsia (early as well as 
late preeclampsia) (Supplementary data, Table 1) [3, 9, 10].
Probabilities of developing CVD for each cycle (Table 1) 
were derived from meta-analyses on cardiovascular dis-
ease [3, 9, 10]. Risk reduction in the intervention group 
for the development of ischaemic heart disease and stroke 
were based on the effects of blood pressure lowering, start-
ing with a pre-treatment systolic blood pressure (SBP) of 
Table 1 Relative risk on cardiovascular outcome in participants with 
untreated hypertension
Health outcome Relative risk (95 % CI) Distribution Reference
Ischaemic heart 
disease
1.32 Fixed 11
Stroke 1.49 Fixed 11
Heart failure 1.47 (1.35–1.61) Normal 12
End-stage renal 
disease
2.57 (2.06–3.22) Normal 13
Cardiovascular 
mortality
1.61 (1.35–1.92) Normal 12
* The ‘cardiovascular event’ health state is subdivided
into ‘ischaemic heart disease’, ‘stroke’, ‘heart failure’
and ‘renal failure’.
No
hypertension
Hypertension
adequately
treated
Hypertension
untreated
Cardio-
vascular
event* 
Cardio-
vascular
mortality
Mortality of
other causes
Fig. 1 Schematic representation of the Markov model
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associated with the potential CVD and yearly ongoing costs 
thereafter were derived from published Dutch cost studies; 
[17, 18] if not available other European studies were used 
[19].
Effects
QALYs were used as outcome measure in the model. To 
measure health-related quality of life we used a single index 
utility, on a scale from 0 (death) to 1 (perfect health). Util-
ity data (Supplementary data, Table 3) were derived from 
recent population-based literature [20, 24]. Because of the 
general  preference  to  enjoy  benefits  as  soon  as  possible, 
future effects were discounted to their present value by a 
rate of 1.5 % [14].
Analysis
Total event rates, life-years, QALYs and expected costs 
were calculated for both strategies. If one strategy was 
more effective and less costly, this strategy was deemed 
cost-effective. If screening was more costly and more 
effective, or the opposite, incremental cost-effectiveness 
140 mmHg and one drug standard dose [11]. As Law et 
al. did not describe the effects of blood pressure lowering 
on heart failure and mortality we used hazard ratios (per 
20 mmHg SBP increase) on CVD mortality and total CVD 
events in a Dutch cohort study (35–65 years of age) to esti-
mate the effects on these health states [12]. Estimation of 
the relative risk for the development of end-stage renal dis-
ease was also based on an SBP difference of 20 mmHg in a 
American cohort of 37 years of age [13].
Costs
Costs (Supplementary data, Table 2) were presented in 
Euros (€). Price indices were used to convert costs to the 
2012 price level, future expenditures were discounted to 
their present value by a rate of 4 % [14]. Estimation of costs 
in the intervention strategy was based on a single screening 
visit at the GP of € 30 (Dutch reference price, as established 
by the Dutch Healthcare Insurance Board) [14]. Costs for 
detection of hypertension in both strategies were based on 
three GP visits and an ECG recording (€ 130) and yearly 
costs for treatment of hypertension and medication use 
according to current Dutch GP guidelines [15, 16]. Costs 
Table 2 Cost-effectiveness results (probabilistic analysis)
Screening strategy Mean (95 % 
credible intervals)
No screening strategy Mean (95 % CI) Increment Mean (95 % CI)
Expected health care costs 
(€/horizon)
10 year horizon 3058 (1893; 5446) 3083 (1755; 5778) – 25 (– 392; 142)
20 year horizon 8016 (4614; 14627) 9087 (4721; 17,785) – 1071 (– 3146; – 87)
Expected life years  
(years/horizon)
9.1716 9.1701 0.0015
10 year horizon (9.1676; 9.1752)
16.9529
(9.1659; 9.1741)
16.9427
(0.0007 0.0022)
0.0102
20 year horizon (16.9390; 16.9660) (16.9259; 16.9583) (0.0053; 0.0158)
Expected QALYs
(QALYs/horizon)
10 year horizon
20 year horizon
8.93 (8.81; 9.03)
16.40 (16.15; 16.65)
8.92 (8.81; 9.02)
16.37 (16.11; 16.63)
0.0046 (0.0020;0.0078)
0.0320
(0.0143; 0.0533)
Table 3 Results of the deterministic threshold and sensitivity analysis (over 20 years)
Incremental costs screening 
(euro/time horizon 20 y)
Incremental QALYs screening 
(QALYs/time horizon 20 y)
Incremental costs per QALY gained
Base case analysis – 1062 0.032 Screening dominates
Costs of screening € 151/y – 4 0.032 Screening dominates
Adherence on medication 75 % – 1024 0.031 Screening dominates
Utility hypertension 0.95 – 1062 0.030 Screening dominates
Utility hypertension 0.90 – 1062 0.026 Screening dominates
Utility untreated hypertension 0.95 – 1062 0.184 Screening dominates
Utility untreated hypertension 0.90 – 1062 0.437 Screening dominates
Utility untreated hypertension 0.90, 
treated hypertension 0.95
– 1062 0.283 Screening dominates
Utility untreated hypertension 0.95, 
treated hypertension 0.97
– 1062 0.133 Screening dominates
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for women with and without hypertension at 0.98 [20], we 
propose that hypertension and use of medication might 
decrease quality of life.
Results
Base-case analysis
Screening for hypertension was found to be slightly more 
effective than no screening (Table 2). Over a time horizon 
of 20 years events occurred in 7.2 % of the population after 
screening, and in 8.5 % of the population without screening. 
Life-years in the screening strategy were 16.9529 versus 
16.9427 per person in the no screening strategy, an incre-
ment of 0.0102 (95 % CI 0.0053; 0.0158) life-years. QALYs 
increased to 16.37 for the no screening strategy and to 16.40 
for the screening strategy, an increment of 0.0320 (95 % CI 
0.0143; 0.0533) QALYs, which equals 12 days in perfect 
health quality.
Screening was also found to be less expensive than no 
screening. Estimated expenditures over a 20-year time hori-
zon in the screening strategy were € 8016, compared with 
€9087 in the no screening strategy. This results in further 
savings of €1071 (95 % CI – 3146; – 87) per person.
Sensitivity analysis
The results of the probabilistic sensitivity analysis showed 
that despite considerable uncertainty, in almost all simula-
tions the screening strategy was less costly and more effec-
tive than the no screening strategy over 20 years (Fig. 2). 
ratios (ICERs) were calculated by dividing the incremen-
tal costs by the incremental QALYs. Whether screening is 
cost-effective depends on whether this ICER is below the 
societal willingness to pay for a QALY. The informal will-
ingness to pay in the Netherlands is € 20,000 per QALY for 
standard health interventions [14].
Sensitivity analysis
To reflect the uncertainty of the parameter estimates in the 
model probabilistic sensitivity analyses were performed 
[25]. For this purpose distributions were assigned to the 
model parameters. Parameter values were drawn at random 
from the assigned distributions, using Monte Carlo simula-
tion with 5000 iterations. Based on these simulations, mean 
values and 2.5th and 97.5th percentiles (95 % credible inter-
vals) surrounding the costs and effects were calculated.
The results of this probabilistic analysis are demonstrated 
in a cost-effectiveness plane and cost-effectiveness accept-
ability curve (CEAC). The CEAC shows the probability that 
screening is cost-effective over a range of willingness-to-
pay thresholds [26].
In addition, a threshold analysis was performed to deter-
mine the maximum costs of screening for which screening 
is the most effective and least expensive strategy.
One-way deterministic sensitivity analyses were per-
formed to evaluate the effect of reduced adherence to 
hypertension treatment in women (75 %), as in common 
clinic practice adherence to antihypertensive medication 
is less than 100 %. Deterministic sensitivity analyses were 
also used to evaluate changes in quality of life of women 
with hypertension. In our primary model we set utility index 
ͲΦϱϬϬϬͲΦϰϬϬϬͲΦϯϬϬϬͲΦϮϬϬϬͲΦϭϬϬϬΦϬ
ΦϭϬϬϬΦϮϬϬϬΦϯϬϬϬΦϰϬϬϬΦϱϬϬϬͲϬ͘ϭϬ ͲϬ͘Ϭϴ ͲϬ͘Ϭϲ ͲϬ͘Ϭϰ ͲϬ͘ϬϮ Ϭ͘ϬϬ Ϭ͘ϬϮ Ϭ͘Ϭϰ Ϭ͘Ϭϲ Ϭ͘Ϭϴ Ϭ͘ϭϬ
/ŶĐƌĞŵĞŶƚĂůĐŽƐƚƐ
/ŶĐƌĞŵĞŶƚĂůY>zƐ
Fig. 2 Effectiveness of screening 
for hypertension post preeclamp-
sia according to the probabilistic 
analysis in 20 year time horizon
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an expected saving of € 1071 per person and a slight incre-
ment of 0.03 QALY (12 days living in perfect health) per 
screened person.
Strengths and limitations
The power of this Markov model is founded in the combina-
tion of the available evidence on CVD post preeclampsia. 
Our model could be of help in making evidence-based deci-
sions on prevention post preeclampsia, without performing 
costly long-term follow-up studies.
However, our model has some limitations. To estimate 
risk of hypertension in women after preeclampsia, we 
used a cohort of women post early preeclampsia. As early 
preeclampsia confers the highest future CVD risk of all 
hypertensive pregnancy disorders [1, 10], the results of our 
Markov model should not be extrapolated to all women post 
hypertensive pregnancy disorders. As future risk for hyper-
tension and CVD are lower in women with late compared 
with early preeclampsia, the magnitude of screening effects 
will be smaller.
Secondly, as prospective data in women after early pre-
eclampsia are relatively scarce, we also used CVD risk 
data of patients with less severe preeclampsia to estimate 
risk of future CVD after preeclampsia. This may have 
underestimated the net effect of hypertension screening on 
CVD risk in women post early preeclampsia in our model. 
Nonetheless, the presented data are convincing and under-
line the need for preventive measures in women post early 
preeclampsia.
In our model we used mainly Dutch costs. As costs in 
other jurisdictions will be different from the Dutch situa-
tion, our results could be less generalisable to other health 
systems. However, in general costs in the US tend to be 
higher than in the Dutch healthcare system, so savings in 
the US will probably be larger. On the other hand, the Dutch 
well-structured GP system can adopt our intervention strat-
egy  easily,  whereas  this  might  be  more  difficult  in  other 
countries.
To perform our model we made some assumptions. First, 
we assumed that women with non-treated hypertension in 
the non-intervention strategy had a 20 mmHg higher SBP 
than women with adequately treated hypertension in the 
intervention strategy, based on our PREVFEM data. This 
seems reliable if women in the intervention strategy are 
directly well controlled and treated, but in current daily 
practice this is disappointing 28 s, in our model participants 
were all compliant in taking their antihypertensive medica-
tion, in real practice a quarter of women on blood pressure 
medication do not take their medication regularly, which 
will reduce the calculated preventive effects [29]. However, 
sensitivity analysis shows that screening remains cost-effec-
tive with an adherence rate of 75 %.
From the CEAC it is clear that regardless of the willing-
ness to pay for a QALY, screening has a probability of being 
cost-effective of over 99 % in 20 years (Fig. 3).
In the threshold analysis, screening remained the least 
costly strategy over 20 years with costs of screening up to 
€ 151 per year.
Table 3 shows the one-way sensitivity analysis on adher-
ence and utility. With an adherence percentage of 75 % cost 
savings decrease to € 1024 and the QALY gain to 0.031, 
but screening remains cost-effective. For each variation in 
utility the screening strategy remained the most effective 
strategy.
Discussion
Several studies have clearly demonstrated the increased risk 
for CVD in women with a history of preeclampsia [1, 3]. 
Especially women after early and severe preeclampsia are 
at higher risk for future CVD [1, 10]. The 2011 American 
Heart Association guidelines on cardiovascular disease pre-
vention in women recognise pregnancy as a unique chance to 
predict women’s lifetime cardiovascular risk, as pregnancy-
related complications may unmask premature vascular or 
metabolic diseases. Therefore, appropriate monitoring of 
CVD risk factors in these high-risk women is recommended 
[5]. The 2012 European Society of Cardiology guideline on 
CVD prevention also indicates that prevention of CVD in 
women ideally starts during pregnancy and lasts until end of 
life [7]. However, in standard primary care obstetric history 
is not yet routinely incorporated in risk assessment [27].
In this model-based analysis we assess the expected cost-
effectiveness of a hypertension screening strategy in women 
after preeclampsia. We found that a relatively simple pre-
ventive strategy, consisting of a yearly blood pressure mea-
surement at the GP’s surgery after index pregnancy, gives 
0
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